Stay Up to Date! Like us on Facebook  and Twitter  for the latest news and announcements    

References

Bakker HD, Scholte HR, Jeneson JA.  Vitamin E in a mitochondrial myopathy with proliferating mitochondria.  Lancet 1993;342(8864):175.

Bennett MJ, Sherwood WG, Gibson KM, Burlina AB.  Secondary inhibition of multiple NAD-requiring dehydogenases in respiratory complex I deficiency: Possible metabolic markers for the primary defect.  J Inher Metab Dis 1993;16:560-62.

Bradley JL, Blake JC, Chamberlain S, et al.  Clinical, biochemical, and molecular genetic correlations in Friedreich's ataxia.  Hum Molec Gen 2000;9(2):275-82.

Brown GK, Scholem RD, Hunt SM, et al.  Hyperammonaemia and lactic acidosis in a patient with pyruvate dehydrogenase deficiency.  J Inher Metab Dis 1987;10(4):359-66.

Chae JH, Hwang H, Lim BC, et al.  Clinical features of A3243G mitochondrial tRNA mutation.  Brain Dev 2004;26:459-62.

Chinnery PF, Bindoff LA.  116th ENMC international workshop: The treatment of mitochondrial disease, 14th-16th March 2003, Naarden, The Netherlands.  Neuromusc Dis 2003;13:757-64.

Clarencon F, Touze E, Leroy-Willig A, et al.  Spastic paraparesis as a manifestation of Leber's disease.  J Neurol 2006;253:525-6.

Coude FX, Ogier H, Marsac C, et al.  Secondary citrullinemia with hyperammonemia in four cases of pyruvate carboxylase deficiency.  Pediatrics 1981;68(6):914-

Darin N, Oldfors A, Moslemi AR, et al.  The incidence of mitochondrial encephalomyopathies in childhood: Clinical features and morphological, biochemical, and DNA abnormalities.  Ann Neurol 2001;49:377-83.

Di Donato S.  Disorders related to mitochondrial membranes: Pathology of the respiratory chain and neurodegeration.  J Inher Metab Dis 2000;23(3):247-63.

DiMauro S, Schon EA.  The mitochondrial respiratory chain and its disorders.  In Mitochondrial Medicine.  DiMauro S, Hirano M, Schon EA, eds.  Informa Healthcare, Abingdon UK, 2006, 7-26.

Eleff S, Kennaway NG, Buist NR, et al.  31P NMR study of improvement in oxidative phosphorylation by vitamins K3 and C in a patient with a defect in electron transport at complex III in skeletal muscle.  PNAS 1984;81(11):3529.

Enns GM, Bennett MJ, Hoppel CL, et al.  Mitochondrial respiratory chain complex I deficiency with clinical and biochemical features of long chain 3-hydoxyacyl-coenzyme A dehydrogenase deficiency.  J Pediatr 2000;136:251-4.

Feillet F, Bodamer OA, Dixon MA, et al.  Resting energy expenditure in disorders of propionate metabolism.  J Pediatr 2000; 136(5):659-63.

Haas RH, Parikh S, Falk MJ, et al.  Mitochondrial disease: A practical approach for primary care physicians.  Pediatrics 2007;120(6):1326-1333.

Hagenfeldt L.  Compromised fatty acid oxidation in mitochondrial disorders.  J Inher Metab Dis 1998;21(5):613-7.

Jeppesen TD, Schwartz M, Olsen DB, et al.  Aerobic training is safe and improves exercise capacity in patients with mitochondrial myopathy.  Brain 2006;129(Pt12):3402-12.

Hayasaka K, Metoki K, Satoh T, et al.  Comparison of cytosolic and mitochondrial enzyme alterations in the livers of propionic and methylmalonic acidemia: A reduction of cytochrome c oxidase activity.  Tohoku J Exp Med 1982;137(3):329-34.

Kendall F.  Personal communication, 2007.

Mahoney D, Parise G, Tarnopolsky MA.  Nutritional and exercise-based therapies in the treatment of mitochondrial disease.  Curr Opin Clin Nutr Metab Care 2002;5(6):619-29.

Mancuso M, Petrozzi L, Filosto M, et al.  MERRF syndrome without ragged-red fibers: The need for molecular diagnosis.  Biochem Biophys Res Comm 2007;354(4):1058-60.

Marriage B, Clandinin MT, Glerum M.  Nutritional cofactor treatment in mitochondrial disorders.  J Am Diet Assoc 2003;103:1029-38.

Morava E, Rodenburg R, van Essen HZ, et al.  Dietary intervention and oxidative phosphorylation capacity.  J Inher Metab Dis 2006;29(4):589.

Morava E, van den Heuvel L, Hol F, et al.  Mitochondrial disease criteria: Diagnostic applications in children.  Neurology 2006:67:1823-6.

Navarro A, Broveria A.  The mitochondrial energy transduction system and aging process.  Am J Physiol - Cell Physiol 2007;292(2):C670-86.

Nonaka I, Koga Y, Shikura K, et al.  Muscle pathology in cytochrome c oxidase deficiency.  Acta Neuropathol 1988;77(2):152-60.

Peterson PL.  The treatment of mitochondrial myopathies and encephalomyopathies.  Biochim Biophys Acta 1995;1271(1):275.

Ponchaut S, van Hoof F, Veithc K.  Cytochrome aa3 depletion is the cause of the deficient mitochondrial respiration induced by chronic valproate administration.  Biochem Pharmacol 1994;43(3):644-7.

Schoenen J, Jacquy J, Lenaerts M.  Effectiveness of high-dose riboflavin in migraine prophylaxis. A randomized controlled trial.  Neurology 1988;50(2):466.

Sembrano E, Barthlen GM, Wallace S, Lamm C.  Polysomnographic findings in a patient with the mitochondrial encephalomyopathy NARP.  Neurology 1997;49:1714-7.

Shoffner JM - A.  Personal communication, 2001.

Shoffner JM - B.  Oxidative phosphorylation diseases.  In Scriver CR, Beaudet Al, Sly WS, Valle D, eds.  The Metabolic and Molecular Bases of Inherited Disease, 8th ed.  McGraw-Hill, New York, 2001.  2391-

Wallace DC.  A mitochondrial paradigm for degenerative diseases and ageing.  Novartis Foundation Symposium 2001;235:247-63; discussion 263-6.

Wray SH, Provenzale JM, Johns DR, Thulborn KR.  MR of the brain in mitochondrial myopathy.  Am J Neuroradiol 1995;16(5):1167-73.

Wyderski RJ. Treatment of migraine.  New Engl J Med 2002;347(10):764.

Yasaki E, Saito Y, Nakano K, et al.  Characteristics of breathing abnormality in Leigh and its overlap syndromes.  Neuropediatrics 2001;32(6):299-306.

Yee AJ. Effectiveness of high-dose riboflavin in migraine prophylaxis.  Neurology 1999;52(2):431.

Yamamoto M, Sato T, Anno M, et al.  Mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes with recurrent abdominal symptoms and coenzyme Q10 administration.  J Neurol, Neurosurg Psychiatry 1987;50:1475.

Ogasahara S, Yorifuji S, Nishikawa Y, et al.  Improvement of abnormal pyruvate metabolism and cardiac conduction defect with coenzyme Q10 in Kearns-Sayre syndrome.  Neurology 1985;35:372.

Ogasahara S, Nishikawa Y, Yorifuji S, et al.  Treatment of Kearns-Sayre syndrome with coenzyme Q10.  Neurology 1986;36:45.

Bet L, Bresolin N, Binda A, et al. Cardiac improvement after coenzyme Q10 treatment in Kearns-Sayre syndrome.  Neurology 1987;37(suppl1):202.

Bresolin N, Bet L, Binda A, et al.  Clinical and biochemical correlations in mitochondrial myopathies treated with coenzyme Q10.  Neurology 1988;38:892.

Desnuelle C, Pellisier JF, Serratrice G, et al.  Chronic progressive external ophthalmoplegia (CPEO) associated with diaphragm paralysis: Successful treatment with coenzyme Q10 (CoQ).  Neurology 1988;38(suppl1):102.

Nishikawa Y, Takahashi M, Yorifuji S, et al.  Long term coenzyme Q10 therapy for a mitochondrial encephalomyopathy with cytochrome c oxidase deficiency: A 31P NMR study.  Neurology 1989;39:399.

Abe K, Fujimura H, Nishikawa Y, et al.  Marked reduction in CSF lactate and pyruvate levels after CoQ therapy in a patient with mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS).  Acta Neurol Scand 1991;83:356.

Bendahan D, Desnuelle C, Vanuxem D, et al.  31P NMR spectroscopy and ergometer exercise test as evidence for muscle oxidative performance improvement with coenzyme Q in mitochondrial myopathies.  Neurology 1992;42:1203.

Zierz S, Jahns G, Jerusalem F.  Coenzyme Q in serum and muscle of five patients with Kearns-Sayre syndrome and 12 patients with ophthalmoplegia plus.  J Neurol 1989;236:97.

Suzuki Y, Taniyama M, Muramatzu T, et al.  Diabetes mellitus associated with 3243 mitochondrial tRNA mutation: Clinical features and coenzyme Q10 treatment.  Mol Aspects Med 1997;18(suppl):S181.

 

Page Security: